Policy changes in opioid agonist therapy and impacts on HIV and hepatitis C prevention in Canadian federal prisons

Nadine Kronfli, Lynn M Madden, Mark Stoové, Olivia Price, Frederick L Altice · 2026

Read Policy changes in opioid agonist therapy and impacts on HIV and hepatitis C prevention in Canadian federal prisons by Nadine Kronfli, Lynn M Madden, Mark Stoové, Olivia Price, Frederick L Altice (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13156621.txt.

Description

Nadine Kronfli and co-authors wrote a 2026 piece on drug therapy policy in Canadian federal prisons and its effect on HIV and hepatitis C control. The prison system had built a strong prevention-first model, with all main opioid therapies, needle programs, and care that doubles as prevention. Rates of both viruses stayed low under that model.

Near half of those entering prison were on such therapy, and about a quarter of all inmates get it inside. A recent policy shift, the authors warn, risks undoing decades of gains by cutting patient choice in which therapy form to take.

Catalog record

CREATORNadine Kronfli, Lynn M Madden, Mark Stoové, Olivia Price, Frederick L Altice
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE6 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13156621

Browse the full library · About the Tower of Babel